Total 19 patients underwent 19 SVC stenting procedures during the study period. All cases were caused by malignant SVCO. 16 patients (84%) had lung cancer.

Technical success and clinical success were achieved in all cases (100%). Post-stenting balloon angioplasty was performed in 11 cases (58%). Figure 1 illustrated a technical success case of SVC stenting.

Intraprocedural complication was detected in 1 case (5%). It was a case of intraprocedural stent migration into the right atrium with close cell stent, managed with additional bridging SVC-IVC stenting (Figure 2), classified as grade 1 complication.

Follow up period ranged from 5 to 339 days (median 38 days). 3 patients (15.8%) had clinical recurrence of symptoms, in which 2 patients had CT performed showing in-stent occlusion (Figure 3).

Regarding stent design, open cell stent (Abre, Medtronic) was used in 8 procedures (42%) while close cell stent (Wallstent, Boston; VICI, Boston; Venovo, BD) was used in 11 procedures (58%). There was no difference in terms of technical success (100% vs 100%), clinical success (100% vs 100%), complication rate (0% vs 9%; p=0.58) and recurrence rate (13% vs 18%; p=0.62) between the open cell and close cell stent groups.